Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 30, 2009, Pages 5023-5030

  De Vos, Sven ^a   Goy, André ^a   Dakhil, Shaker R ^a   Saleh, Mansoor N ^a   McLaughlin, Peter ^a   Belt, Robert ^a   Flowers, Christopher R ^a   Knapp, Mark ^a   Hart, Lowell ^a   Patel Donnelly, Dipti ^a   Glenn, Martha ^a   Gregory, Stephanie A ^a   Holladay, Charles ^a   Zhang, Tracy ^a   Boral, Anthony L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; RITUXIMAB;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; METABOLIC ACIDOSIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME;

EID: 77349086121     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.7980     Document Type: Article

References (56)

1. Chiu BC, Weisenburger DD: An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 4:161-168, 2003
2. Fisher SG, Fisher RI: The epidemiology of non-Hodgkin's lymphoma. Oncogene 23:6524-6534, 2004
3. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2008. CA Cancer J Clin 58:71-96, 2008
4. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488, 2005
5. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997
6. Archuleta TD, Armitage JO: Advances in follicular lymphoma. Semin Oncol 31:66-71, 2004
7. Thieblemont C: Clinical presentation and management of marginal zone lymphomas. Am Soc Hematol Educ Program 307-313, 2005
8. Maloney DG: Treatment of follicular non-Hodgkin's lymphoma. Curr Hematol Rep 4:39-45, 2005
9. Hiddemann W, Buske C, Dreyling M, et al: Current management of follicular lymphomas. Br J Haematol 136:191-202, 2007
10. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
11. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005
12. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006
13. Solal-Cé ligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
14. Buske C, Hoster E, Dreyling M, et al: The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504-1508, 2006
15. Schulz H, Bohlius J, Skoetz N, et al: Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 4:CD003805, 2007
16. Buske C, Weigert O, Dreyling M, et al: Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 91:104-112, 2006
17. Pileri SA, Zinzani PL, Went P, et al: Indolent lymphoma: The pathologist's viewpoint. Ann Oncol 15:12-18, 2004
18. Bertoni F, Zucca E: State-of-the-art therapeutics: Marginal-zone lymphoma. J Clin Oncol 23:6415-6420, 2005
19. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
20. Davis TA, White CA, Grillo-Lopez AJ, et al: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol 17:1851-1857, 1999
21. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004
22. Cohen Y, Solal-Celigny P, Polliack A: Rituximab therapy for follicular lymphoma: A comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica 88:811-823, 2003
23. Paoluzzi L, O'Connor OA: Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 20:13-23, 2006
24. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
25. O'Connor O, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005
26. O'Connor OA, Wright J, Moskowitz C, et al: Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicenter phase II experience. Ann Oncol 16: v66, 2005 (suppl 5; abstr 099)
27. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
28. Strauss SJ, Maharaj L, Hoare S, et al: Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 24:2105-2112, 2006
29. O'Connor O, Hamlin P, Moskowitz C, et al: Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL). J Clin Oncol 25:453s, 2007 (abstr 8051)
30. Conconi A, Lopez-Guillermo A, Martinelli G, et al: Activity of bortezomib in MALT lymphomas: A IELSG phase II study. Ann Oncol 19:iv191, 2008 (abstr 368)
31. Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360, 2004
32. Rajkumar SV, Richardson PG, Hideshima T, et al: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639, 2005
33. Fahy BN, Schlieman MG, Mortenson MM, et al: Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56:46-54, 2005
34. Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144, 2003
35. Ailawadhi S, Mashtare TL, Coignet MV, et al: Bcl-2 translocation [t(14;18) (q32;q21)] does not correlate with poor clinical outcome in multiple myeloma patients treated with bortezomib. Blood 110: 448a, 2007 (abstr 1498)
36. Hernandez-Ilizaliturri FJ, Kotowski A, Czuczman MS: PS341 inhibits cell proliferation, induces apoptosis of and enhances the biological effects of rituximab on non-Hodgkins lymphoma (NHL) cell lines and lymphoma xenografts. Blood 102:903a, 2003 (abstr 3359)
37. De Vos S, McBride W, Calimlim J, et al: Active combination therapy of bortezomib and rituximab in an in vitro and in vivo DLBCL mode. Proc Am Assoc Cancer Res 45:126, 2004 (abstr 546)
38. Smolewski P, Duechler M, Linke A, et al: Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res 30:1521-1529, 2006
39. Cartron G, Blasco H, Paintaud G, et al: Pharmacokinetics of rituximab and its clinical use: Thought for the best use? Crit Rev Oncol Hematol 62:43-52, 2007
40. Millennium Pharmaceuticals Inc: VELCADE (bortezomib) for Injection: Prescribing information. Cambridge, MA, June 2008, Rev 9, 2008
41. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
42. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
43. National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer .gov/forms/CTCAEv3.pdf.
44. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
45. White SJ, Freedman LS: Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 37:849-857, 1978
46. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
47. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
48. Fisher RI, Bernstein SH, Kahl BS, et al: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867-4874, 2006
49. Papandreou CN, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121, 2004
50. Dreicer R, Petrylak D, Agus D, et al: Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13:1208-1215, 2007
51. Hainsworth JD, Spigel DR, Barton J, et al: Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: A phase 2 trial of the Minnie Pearl Cancer Res Network. Cancer 113:765-771, 2008
52. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120, 2006
53. De Vos S, Dakhil SR, McLaughlin P, et al: Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results. Blood 108:208a, 2006 (abstr 694)
54. Sebban C, Brice P, Delarue R, et al: Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study. J Clin Oncol 26:3614-3620, 2008
55. Davis TA, Grillo-Lopez AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
56. Gerecitano J, Portlock C, Hamlin P, et al: A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas. J Clin Oncol 26:457s, 2008 (abstr 8512)